UNLOCKING THE POTENTIAL OF THE
IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Immunophotonics uses a proprietary glycan polymer with
platform potential to stimulate antigen capture and uptake along
with other immunological processes that are intended to trigger an
immune response, thereby enabling the rejection of cancer and other diseases.
Read More

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses.
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases.

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

The Latest News

November 8, 2022

Wei Chen’s Paper Publication in the Journal for ImmunoTherapy of Cancer (JITC)

Congratulations to Professor Wei Chen and his lab at the University of Oklahoma for their publication in one of the...
Read More
October 26, 2022

Immunophotonics Co-Founder Wei Chen, Ph.D. Awarded $2.5 Million Grant by the National Cancer Institute

Immunophotonics, Inc. would like to congratulate Wei Chen, Ph.D. on his recently awarded Grant by the National Cancer Institute of...
Read More
October 13, 2022

Bio-Europe 2022, October 24 – 26

Dr. Theresa Visarius, Immunophotonics Vice President of Business Development and Managing Director of Immunophotonics Switzerland will be attending Bio-Europe 2022...
Read More
1 2 3 13